AMPLIA THERAPEUTICS LIMITED - Announcements

10.8%

20.5¢

Market Cap $99.72M

Healthcare Biotechnology

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ATX	Response to ASX Price Query	PRICE SENSITIVE	11/07/17	169.59KB	Share
ATX	Change of Director's Interest Notice - A. Sneddon		29/06/17	618.37KB	Share
ATX	Change of Director's Interest Notice - M. Quinn		29/06/17	618.12KB	Share
ATX	Top-Line Results for Trial of MIS416	PRICE SENSITIVE	27/06/17	528.48KB	Share
ATX	Trading Halt	PRICE SENSITIVE	23/06/17	326.24KB	Share
ATX	Full Year Statutory Accounts - Year Ended 31 March 2017		22/06/17	552.17KB	Share
ATX	FDA Clearance - MIS416 Investigational New Drug Application	PRICE SENSITIVE	21/06/17	368.33KB	Share
ATX	Preliminary Final Report - Year Ended 31 March 2017	PRICE SENSITIVE	31/05/17	252.45KB	Share
ATX	American Academy of Neurologists Posters & KOL Presentation		01/05/17	1.62MB	Share
ATX	Appendix 4C - March 17 Quarter Statement of Cash Flows	PRICE SENSITIVE	28/04/17	655.95KB	Share
ATX	Completion of Phase 2B Trial of MIS416	PRICE SENSITIVE	20/04/17	383.67KB	Share
ATX	Grant of Options to Chief Executive Officer		19/04/17	402.65KB	Share
ATX	Section 708A Cleansing Statement - Placement		24/03/17	446.52KB	Share
ATX	Appendix 3B - Placement		24/03/17	659.19KB	Share
ATX	Private Placement to raise Additional Working Capital	PRICE SENSITIVE	17/03/17	392.4KB	Share
ATX	Trading Halt	PRICE SENSITIVE	16/03/17	618.44KB	Share
ATX	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	10/03/17	177.37KB	Share
ATX	Extracts Re MIS416 Accepted at American Academy Neurologists		07/03/17	377.16KB	Share
ATX	Phase 2B Trial of MIS416 on Schedule to Complete April 2017	PRICE SENSITIVE	28/02/17	372.37KB	Share
ATX	Change of Director's Interest Notice - Simon Wilkinson		21/02/17	610.01KB	Share
ATX	Appendix 3B - Exercise of Employee Options		20/02/17	657.06KB	Share
ATX	TOV: IIL Panel Declines to Conduct Proceedings	PRICE SENSITIVE	20/02/17	73.18KB	Share
ATX	Innate Immunotherapeutics Limited Panel Receives Application		15/02/17	94.54KB	Share
ATX	Appendix 3B - Exercise of Employee Options		06/02/17	653.78KB	Share
ATX	Appendix 4C - Dec 2016 Quarter Statement of Cashflows	PRICE SENSITIVE	31/01/17	654.86KB	Share
ATX	Response to ASX Price Query	PRICE SENSITIVE	27/01/17	773.02KB	Share
ATX	Ceasing to be a substantial holder from AEF		24/01/17	339.53KB	Share
ATX	Change in substantial shareholding from AEF		19/01/17	349.94KB	Share
ATX	Biotech Showcase Presentation		10/01/17	1.61MB	Share
ATX	Response to Price Query	PRICE SENSITIVE	30/12/16	504.92KB	Share
ATX	Change Director's Interest - Wilkinson Loyalty Rights Expire		19/12/16	616.25KB	Share
ATX	Change Director's Interest - Collins Loyalty Rights Expire		19/12/16	612.91KB	Share
ATX	Change of Director's Interest - M Quinn Loyalty Right Expire		19/12/16	619.6KB	Share
ATX	Loyalty Rights Expire		19/12/16	366.65KB	Share
ATX	Change in substantial holding from AEF		02/12/16	348.74KB	Share
ATX	App 4D - Half Yearly Report and Accounts HY ended 30 Sep 16	PRICE SENSITIVE	29/11/16	531.05KB	Share
ATX	Presentation to ASX FNN CEO Sessions Investor Forum		22/11/16	477.25KB	Share
ATX	Phase 2B Update - Patients Wanting Access to Drug Post Trial	PRICE SENSITIVE	07/11/16	370.49KB	Share
ATX	Appendix 4C - Quarterly Cashflows Report - Sept 2016 Qtr-IIL.AX	PRICE SENSITIVE	31/10/16	668.82KB	Share
ATX	Change in substantial holding from AEF,AEF-IIL.AX		24/10/16	347.67KB	Share
ATX	Change in substantial holding for IIL,IIL-AEF.AX		14/10/16	347.97KB	Share
ATX	Section 708A - Cleansing Notice Final Allotment Placement 2-IIL.AX		26/09/16	330.57KB	Share
ATX	Appendix 3B - Final Allotment of Placement 2 Shares-IIL.AX		26/09/16	548.76KB	Share
ATX	Change in substantial holding from AEF,AEF-IIL.AX		15/09/16	350.25KB	Share
ATX	Change in substantial holding - Chris Collins-IIL.AX		15/09/16	105.3KB	Share
ATX	Revised App 3Y - Elizabeth Hopkins-IIL.AX		14/09/16	761.35KB	Share
ATX	Change of Director's Interest Notice - Dr. Robert Peach-IIL.AX		12/09/16	496.89KB	Share
ATX	Change of Director's Interest Notice - Elizabeth Hopkins-IIL.AX		12/09/16	495.94KB	Share
ATX	Change of Director's Interest Notice - Andrew Sneddon-IIL.AX		12/09/16	504.8KB	Share
ATX	Change of Director's Interest Notice - Chris Collins-IIL.AX		12/09/16	501.71KB	Share
ATX	Change of Director's Interest Notice - Simon Wilkinson-IIL.AX		12/09/16	501.42KB	Share
ATX	Change of Director's Interest Notice - Michael Quinn-IIL.AX		12/09/16	507.49KB	Share
ATX	Section 708A Cleansing Notice Placements 1 and 2-IIL.AX		12/09/16	330.94KB	Share
ATX	Appendix 3B Placements 1 and 2 and Options post AGM.-IIL.AX		12/09/16	554.87KB	Share
ATX	Results of Annual General Meeting-IIL.AX		31/08/16	505.9KB	Share
ATX	Clinical Trials Update - 2016 Bioshares Biotech Summit-IIL.AX	PRICE SENSITIVE	02/08/16	1013.24KB	Share
ATX	Appendix 4G - Key to Corporate Governance Disclosures-IIL.AX		29/07/16	219.65KB	Share
ATX	2016 Corporate Governance Statement-IIL.AX		29/07/16	389.59KB	Share
ATX	Annual Report to shareholders - YE 31 March 2016-IIL.AX		29/07/16	1.43MB	Share
ATX	Notice of Annual General Meeting/Proxy Form-IIL.AX		29/07/16	673.13KB	Share
ATX	Appendix 4C - quarterly - June 16 Qtr-IIL.AX	PRICE SENSITIVE	29/07/16	505.79KB	Share
ATX	Change in substantial holding from AEF,AEF-IIL.AX		20/07/16	445.56KB	Share
ATX	Final Stage of Capital Raising Programme Completed-IIL.AX	PRICE SENSITIVE	20/07/16	258.66KB	Share
ATX	Change Director's Interest - Andrew Sneddon - Rights Issue-IIL.AX		14/07/16	494.77KB	Share
ATX	Change of Director's Interest - Michael Quinn - Rights Issue-IIL.AX		14/07/16	502.75KB	Share
ATX	Change Director's Interest - Simon Wilkinson - Rights Issue-IIL.AX		13/07/16	497.35KB	Share
ATX	Rights Issue Strongly Supported-IIL.AX		07/07/16	261.67KB	Share
ATX	Full Year Statutory Accounts - YE 31 March 2016-IIL.AX		22/06/16	944.95KB	Share
ATX	Rights Issue Cleansing Notice-IIL.AX		10/06/16	217.08KB	Share
ATX	Rights Issue Booklet-IIL.AX	PRICE SENSITIVE	10/06/16	563.32KB	Share
ATX	Appendix 3B - Rights Issue-IIL.AX		10/06/16	573.39KB	Share
ATX	Placement & Rights Issue to Raise Additional Working Capital-IIL.AX	PRICE SENSITIVE	10/06/16	276.88KB	Share
ATX	Preliminary Final Report - YE 31 March 2016-IIL.AX	PRICE SENSITIVE	31/05/16	68.31KB	Share
ATX	Video of Corporate Presentation-IIL.AX		03/05/16	233.13KB	Share
ATX	Appendix 4C - Statement of Cashflows March 2016 Qtr-IIL.AX	PRICE SENSITIVE	29/04/16	500.84KB	Share
ATX	Appendix 3B - Employee Options-IIL.AX		28/04/16	568.7KB	Share
ATX	Change of Director's Interest Notice - Michael Quinn-IIL.AX		19/04/16	503.69KB	Share
ATX	Trial Recruitment Complete - Interview with CEO-IIL.AX		15/04/16	233.35KB	Share
ATX	Clinical Trial Fully Enrolled and Strong Interest-IIL.AX	PRICE SENSITIVE	13/04/16	252.77KB	Share
ATX	Change of Director's Interest Notice - Andrew Sneddon		09/03/16	495.1KB	Share
ATX	Change of Director's Interest Notice - Andrew Sneddon		02/03/16	496.29KB	Share
ATX	Appendix 4C - Dec 2015 Quarterly Cash Flow Report	PRICE SENSITIVE	29/01/16	528.87KB	Share
ATX	Appendix 3B - Quotation - End of Restriction Period		24/12/15	540.03KB	Share
ATX	Change of Director's Interest - A Sneddon Options Expired		18/12/15	497.94KB	Share
ATX	Change of Director's Interest - C Collins Options Expire		18/12/15	494.5KB	Share
ATX	Change of Director's Interest - M Quinn Options Expire		18/12/15	502.54KB	Share
ATX	Securities to be Released from Escrow		08/12/15	243.21KB	Share
ATX	Half Yearly Report and Accounts	PRICE SENSITIVE	30/11/15	171.87KB	Share
ATX	Change in substantial holding - Christopher Collins		23/11/15	88.83KB	Share
ATX	Change of Director's Interest - Andrew Sneddon - Placement		20/11/15	404.6KB	Share
ATX	Change of Director's Interest - Michael Quinn - Placement		20/11/15	407.94KB	Share
ATX	Change of Director's Interest - Chris Collins - Placement		20/11/15	400.96KB	Share
ATX	Placement - Section 708(A) Cleansing Statement		20/11/15	268.5KB	Share
ATX	Appendix 3B - Placement		20/11/15	503.33KB	Share
ATX	Appendix 4C - Quarterly Cash Flow Report Sept 15 Qtr	PRICE SENSITIVE	30/10/15	443.98KB	Share
ATX	Results of Meeting - General Meeting to approve Placement		30/10/15	289.66KB	Share
ATX	Notice of General Meeting/Proxy Form - Placement		25/09/15	692.02KB	Share
ATX	Compassionate Use Program Update	PRICE SENSITIVE	25/09/15	214.32KB	Share
ATX	Placement to Raise Additional Working Capital	PRICE SENSITIVE	21/09/15	198.78KB	Share
ATX	Trading Halt	PRICE SENSITIVE	17/09/15	384.05KB	Share

ATX Response to ASX Price Query
11/07/17	PRICE SENSITIVE	169.59KB	Share
ATX Change of Director's Interest Notice - A. Sneddon
29/06/17		618.37KB	Share
ATX Change of Director's Interest Notice - M. Quinn
29/06/17		618.12KB	Share
ATX Top-Line Results for Trial of MIS416
27/06/17	PRICE SENSITIVE	528.48KB	Share
ATX Trading Halt
23/06/17	PRICE SENSITIVE	326.24KB	Share
ATX Full Year Statutory Accounts - Year Ended 31 March 2017
22/06/17		552.17KB	Share
ATX FDA Clearance - MIS416 Investigational New Drug Application
21/06/17	PRICE SENSITIVE	368.33KB	Share
ATX Preliminary Final Report - Year Ended 31 March 2017
31/05/17	PRICE SENSITIVE	252.45KB	Share
ATX American Academy of Neurologists Posters & KOL Presentation
01/05/17		1.62MB	Share
ATX Appendix 4C - March 17 Quarter Statement of Cash Flows
28/04/17	PRICE SENSITIVE	655.95KB	Share
ATX Completion of Phase 2B Trial of MIS416
20/04/17	PRICE SENSITIVE	383.67KB	Share
ATX Grant of Options to Chief Executive Officer
19/04/17		402.65KB	Share
ATX Section 708A Cleansing Statement - Placement
24/03/17		446.52KB	Share
ATX Appendix 3B - Placement
24/03/17		659.19KB	Share
ATX Private Placement to raise Additional Working Capital
17/03/17	PRICE SENSITIVE	392.4KB	Share
ATX Trading Halt
16/03/17	PRICE SENSITIVE	618.44KB	Share
ATX S&P DJ Indices Announces March Quarterly Rebalance
10/03/17	PRICE SENSITIVE	177.37KB	Share
ATX Extracts Re MIS416 Accepted at American Academy Neurologists
07/03/17		377.16KB	Share
ATX Phase 2B Trial of MIS416 on Schedule to Complete April 2017
28/02/17	PRICE SENSITIVE	372.37KB	Share
ATX Change of Director's Interest Notice - Simon Wilkinson
21/02/17		610.01KB	Share
ATX Appendix 3B - Exercise of Employee Options
20/02/17		657.06KB	Share
ATX TOV: IIL Panel Declines to Conduct Proceedings
20/02/17	PRICE SENSITIVE	73.18KB	Share
ATX Innate Immunotherapeutics Limited Panel Receives Application
15/02/17		94.54KB	Share
ATX Appendix 3B - Exercise of Employee Options
06/02/17		653.78KB	Share
ATX Appendix 4C - Dec 2016 Quarter Statement of Cashflows
31/01/17	PRICE SENSITIVE	654.86KB	Share
ATX Response to ASX Price Query
27/01/17	PRICE SENSITIVE	773.02KB	Share
ATX Ceasing to be a substantial holder from AEF
24/01/17		339.53KB	Share
ATX Change in substantial shareholding from AEF
19/01/17		349.94KB	Share
ATX Biotech Showcase Presentation
10/01/17		1.61MB	Share
ATX Response to Price Query
30/12/16	PRICE SENSITIVE	504.92KB	Share
ATX Change Director's Interest - Wilkinson Loyalty Rights Expire
19/12/16		616.25KB	Share
ATX Change Director's Interest - Collins Loyalty Rights Expire
19/12/16		612.91KB	Share
ATX Change of Director's Interest - M Quinn Loyalty Right Expire
19/12/16		619.6KB	Share
ATX Loyalty Rights Expire
19/12/16		366.65KB	Share
ATX Change in substantial holding from AEF
02/12/16		348.74KB	Share
ATX App 4D - Half Yearly Report and Accounts HY ended 30 Sep 16
29/11/16	PRICE SENSITIVE	531.05KB	Share
ATX Presentation to ASX FNN CEO Sessions Investor Forum
22/11/16		477.25KB	Share
ATX Phase 2B Update - Patients Wanting Access to Drug Post Trial
07/11/16	PRICE SENSITIVE	370.49KB	Share
ATX Appendix 4C - Quarterly Cashflows Report - Sept 2016 Qtr-IIL.AX
31/10/16	PRICE SENSITIVE	668.82KB	Share
ATX Change in substantial holding from AEF,AEF-IIL.AX
24/10/16		347.67KB	Share
ATX Change in substantial holding for IIL,IIL-AEF.AX
14/10/16		347.97KB	Share
ATX Section 708A - Cleansing Notice Final Allotment Placement 2-IIL.AX
26/09/16		330.57KB	Share
ATX Appendix 3B - Final Allotment of Placement 2 Shares-IIL.AX
26/09/16		548.76KB	Share
ATX Change in substantial holding from AEF,AEF-IIL.AX
15/09/16		350.25KB	Share
ATX Change in substantial holding - Chris Collins-IIL.AX
15/09/16		105.3KB	Share
ATX Revised App 3Y - Elizabeth Hopkins-IIL.AX
14/09/16		761.35KB	Share
ATX Change of Director's Interest Notice - Dr. Robert Peach-IIL.AX
12/09/16		496.89KB	Share
ATX Change of Director's Interest Notice - Elizabeth Hopkins-IIL.AX
12/09/16		495.94KB	Share
ATX Change of Director's Interest Notice - Andrew Sneddon-IIL.AX
12/09/16		504.8KB	Share
ATX Change of Director's Interest Notice - Chris Collins-IIL.AX
12/09/16		501.71KB	Share
ATX Change of Director's Interest Notice - Simon Wilkinson-IIL.AX
12/09/16		501.42KB	Share
ATX Change of Director's Interest Notice - Michael Quinn-IIL.AX
12/09/16		507.49KB	Share
ATX Section 708A Cleansing Notice Placements 1 and 2-IIL.AX
12/09/16		330.94KB	Share
ATX Appendix 3B Placements 1 and 2 and Options post AGM.-IIL.AX
12/09/16		554.87KB	Share
ATX Results of Annual General Meeting-IIL.AX
31/08/16		505.9KB	Share
ATX Clinical Trials Update - 2016 Bioshares Biotech Summit-IIL.AX
02/08/16	PRICE SENSITIVE	1013.24KB	Share
ATX Appendix 4G - Key to Corporate Governance Disclosures-IIL.AX
29/07/16		219.65KB	Share
ATX 2016 Corporate Governance Statement-IIL.AX
29/07/16		389.59KB	Share
ATX Annual Report to shareholders - YE 31 March 2016-IIL.AX
29/07/16		1.43MB	Share
ATX Notice of Annual General Meeting/Proxy Form-IIL.AX
29/07/16		673.13KB	Share
ATX Appendix 4C - quarterly - June 16 Qtr-IIL.AX
29/07/16	PRICE SENSITIVE	505.79KB	Share
ATX Change in substantial holding from AEF,AEF-IIL.AX
20/07/16		445.56KB	Share
ATX Final Stage of Capital Raising Programme Completed-IIL.AX
20/07/16	PRICE SENSITIVE	258.66KB	Share
ATX Change Director's Interest - Andrew Sneddon - Rights Issue-IIL.AX
14/07/16		494.77KB	Share
ATX Change of Director's Interest - Michael Quinn - Rights Issue-IIL.AX
14/07/16		502.75KB	Share
ATX Change Director's Interest - Simon Wilkinson - Rights Issue-IIL.AX
13/07/16		497.35KB	Share
ATX Rights Issue Strongly Supported-IIL.AX
07/07/16		261.67KB	Share
ATX Full Year Statutory Accounts - YE 31 March 2016-IIL.AX
22/06/16		944.95KB	Share
ATX Rights Issue Cleansing Notice-IIL.AX
10/06/16		217.08KB	Share
ATX Rights Issue Booklet-IIL.AX
10/06/16	PRICE SENSITIVE	563.32KB	Share
ATX Appendix 3B - Rights Issue-IIL.AX
10/06/16		573.39KB	Share
ATX Placement & Rights Issue to Raise Additional Working Capital-IIL.AX
10/06/16	PRICE SENSITIVE	276.88KB	Share
ATX Preliminary Final Report - YE 31 March 2016-IIL.AX
31/05/16	PRICE SENSITIVE	68.31KB	Share
ATX Video of Corporate Presentation-IIL.AX
03/05/16		233.13KB	Share
ATX Appendix 4C - Statement of Cashflows March 2016 Qtr-IIL.AX
29/04/16	PRICE SENSITIVE	500.84KB	Share
ATX Appendix 3B - Employee Options-IIL.AX
28/04/16		568.7KB	Share
ATX Change of Director's Interest Notice - Michael Quinn-IIL.AX
19/04/16		503.69KB	Share
ATX Trial Recruitment Complete - Interview with CEO-IIL.AX
15/04/16		233.35KB	Share
ATX Clinical Trial Fully Enrolled and Strong Interest-IIL.AX
13/04/16	PRICE SENSITIVE	252.77KB	Share
ATX Change of Director's Interest Notice - Andrew Sneddon
09/03/16		495.1KB	Share
ATX Change of Director's Interest Notice - Andrew Sneddon
02/03/16		496.29KB	Share
ATX Appendix 4C - Dec 2015 Quarterly Cash Flow Report
29/01/16	PRICE SENSITIVE	528.87KB	Share
ATX Appendix 3B - Quotation - End of Restriction Period
24/12/15		540.03KB	Share
ATX Change of Director's Interest - A Sneddon Options Expired
18/12/15		497.94KB	Share
ATX Change of Director's Interest - C Collins Options Expire
18/12/15		494.5KB	Share
ATX Change of Director's Interest - M Quinn Options Expire
18/12/15		502.54KB	Share
ATX Securities to be Released from Escrow
08/12/15		243.21KB	Share
ATX Half Yearly Report and Accounts
30/11/15	PRICE SENSITIVE	171.87KB	Share
ATX Change in substantial holding - Christopher Collins
23/11/15		88.83KB	Share
ATX Change of Director's Interest - Andrew Sneddon - Placement
20/11/15		404.6KB	Share
ATX Change of Director's Interest - Michael Quinn - Placement
20/11/15		407.94KB	Share
ATX Change of Director's Interest - Chris Collins - Placement
20/11/15		400.96KB	Share
ATX Placement - Section 708(A) Cleansing Statement
20/11/15		268.5KB	Share
ATX Appendix 3B - Placement
20/11/15		503.33KB	Share
ATX Appendix 4C - Quarterly Cash Flow Report Sept 15 Qtr
30/10/15	PRICE SENSITIVE	443.98KB	Share
ATX Results of Meeting - General Meeting to approve Placement
30/10/15		289.66KB	Share
ATX Notice of General Meeting/Proxy Form - Placement
25/09/15		692.02KB	Share
ATX Compassionate Use Program Update
25/09/15	PRICE SENSITIVE	214.32KB	Share
ATX Placement to Raise Additional Working Capital
21/09/15	PRICE SENSITIVE	198.78KB	Share
ATX Trading Halt
17/09/15	PRICE SENSITIVE	384.05KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 20.5¢		Change 0.020(10.8%)		Mkt cap ! $99.72M

Open	High	Low	Value	Volume
19.0¢	20.5¢	19.0¢	$998.1K	5.012M

Buyers (Bids)

No.	Vol.	Price($)
1	10390	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
20.5¢	199189	6

View Market Depth

No.	Vol.	Price($)
1	10390	0.200
8	238557	0.195
13	488321	0.190
9	487553	0.185
11	387099	0.180

Price($)	Vol.	No.
0.205	199189	6
0.210	318500	9
0.215	300000	3
0.220	529263	4
0.225	430135	5

Last trade - 16.20pm 08/08/2025 (20 minute delay)

ATX (ASX) Chart

AMPLIA THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available